According to Hirsch and Pringsheim (2016),
“Evidence from this review shows that use of aripiprazole for the short-term treatment of irritability in children/adolescents with ASD may be worth considering. If the decision is made to use aripiprazole, clinicians should follow established best practice and provide information about side effects such as weight gain, tremor, drooling and sedation to children/adolescents and their families, so they can consider the benefits and risks of treatment before commencing a medication trial. Children/adolescents undergoing a trial of therapy with aripiprazole should be monitored for clinical effectiveness of the medication, as well as for side effects. In the absence of high-quality evidence, and given that similar relapse rates are observed for both aripiprazole and placebo, evidence suggests that the use of aripiprazole should be re-evaluated periodically for continued efficacy, and that it might be appropriate to consider discontinuation of aripiprazole after successful treatment for 12 weeks.”